Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 22 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-3.79 Insider Own8.63% Shs Outstand104.22M Perf Week-8.31%
Market Cap379.36M Forward P/E- EPS next Y-0.66 Insider Trans0.01% Shs Float95.22M Perf Month-29.87%
Income-323.99M PEG- EPS next Q-0.55 Inst Own75.49% Short Float14.23% Perf Quarter-39.64%
Sales234.04M P/S1.62 EPS this Y23.04% Inst Trans13.79% Short Ratio7.64 Perf Half Y-58.16%
Book/sh-1.72 P/B- EPS next Y56.44% ROA-61.11% Short Interest13.55M Perf Year-88.80%
Cash/sh2.44 P/C1.49 EPS next 5Y11.60% ROE-2096.78% 52W Range3.62 - 37.98 Perf YTD-58.59%
Dividend Est.- P/FCF- EPS past 5Y0.57% ROI-102.54% 52W High-90.42% Beta1.15
Dividend TTM- Quick Ratio3.29 Sales past 5Y815.27% Gross Margin62.38% 52W Low0.41% ATR (14)0.31
Dividend Ex-Date- Current Ratio3.80 EPS Y/Y TTM21.27% Oper. Margin-94.31% RSI (14)27.96 Volatility5.58% 6.13%
Employees597 Debt/Eq- Sales Y/Y TTM76.55% Profit Margin-138.43% Recom1.75 Target Price14.91
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q66.08% Payout- Rel Volume1.02 Prev Close3.78
Sales Surprise12.37% EPS Surprise23.89% Sales Q/Q39.82% EarningsFeb 28 AMC Avg Volume1.77M Price3.64
SMA20-17.20% SMA50-30.09% SMA200-65.37% Trades Volume1,812,734 Change-3.70%
Date Action Analyst Rating Change Price Target Change
Jan-29-24Downgrade Mizuho Buy → Neutral $16 → $9
Jan-09-24Downgrade Goldman Buy → Neutral $30 → $8
Aug-16-23Upgrade Exane BNP Paribas Underperform → Neutral $20
Oct-11-22Initiated Morgan Stanley Equal-Weight $27
Sep-22-22Initiated Goldman Buy $33
Oct-25-21Downgrade Wells Fargo Overweight → Equal Weight $35 → $17
Oct-15-20Reiterated Needham Buy $36 → $42
Aug-11-20Resumed Mizuho Buy $32
Mar-23-20Downgrade Goldman Buy → Neutral $32 → $15
Dec-02-19Initiated Goldman Buy
Apr-12-24 08:00AM
Mar-27-24 04:05PM
Mar-04-24 09:25AM
Mar-02-24 08:23AM
06:41AM Loading…
Feb-29-24 06:41AM
Feb-28-24 04:43PM
Feb-21-24 08:01AM
Feb-02-24 08:00AM
Feb-01-24 08:00AM
Jan-08-24 08:00AM
Nov-09-23 07:05PM
07:00PM Loading…
Nov-08-23 07:00PM
Nov-06-23 08:00AM
Nov-01-23 08:00AM
Oct-26-23 08:00AM
Oct-14-23 01:15PM
Sep-19-23 04:18PM
Sep-06-23 02:27PM
Aug-29-23 12:43AM
Aug-22-23 10:43AM
Aug-21-23 04:09AM
04:03PM Loading…
Aug-14-23 04:03PM
Aug-08-23 06:15PM
Aug-03-23 09:19AM
Aug-01-23 08:00AM
Jul-29-23 11:39AM
Jul-13-23 03:00PM
Jun-29-23 06:20AM
Jun-21-23 08:41PM
May-23-23 04:05PM
May-17-23 06:35AM
May-16-23 02:34AM
May-10-23 10:45AM
May-09-23 06:05PM
May-02-23 10:01AM
Apr-18-23 08:41AM
Apr-05-23 08:00AM
Apr-04-23 11:15PM
Mar-30-23 08:00AM
Mar-29-23 05:36AM
Mar-07-23 08:00AM
Mar-03-23 08:11PM
Mar-01-23 10:33AM
Feb-28-23 07:45PM
Feb-27-23 08:00AM
Feb-24-23 05:10PM
Feb-23-23 08:00AM
Feb-22-23 10:00AM
Feb-21-23 04:05PM
Feb-20-23 10:00AM
Feb-03-23 02:15PM
Feb-02-23 12:00PM
Jan-30-23 10:20AM
Jan-27-23 12:47PM
Jan-23-23 04:14AM
Jan-09-23 08:00AM
Jan-06-23 06:00PM
Nov-22-22 08:00AM
Nov-17-22 08:00AM
Nov-10-22 05:32AM
Nov-09-22 08:00AM
Nov-08-22 06:05PM
Nov-04-22 08:00AM
Nov-02-22 10:01AM
Nov-01-22 01:01PM
Oct-24-22 12:02PM
Oct-20-22 08:00AM
Oct-17-22 08:00AM
Oct-10-22 08:00AM
Sep-21-22 08:00AM
Sep-19-22 08:00AM
Sep-17-22 08:36AM
Sep-15-22 04:06PM
Sep-12-22 09:32PM
Sep-09-22 03:10PM
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jordan EricaChief Commercial OfficerApr 16 '24Sale3.802,3929,096114,864Apr 17 04:34 PM
Schilke TobinCFOMar 18 '24Sale5.049,36147,204192,666Mar 19 06:44 PM
Sjuts Dustin SPresidentMar 18 '24Sale5.049,21146,446167,550Mar 19 06:45 PM
Moxie DwightCLO & GCMar 18 '24Sale5.048,12540,971137,815Mar 19 06:44 PM
Foley Mark JCEOMar 06 '24Buy6.9830,000209,4001,015,468Mar 08 04:33 PM
Moxie DwightSVP, GC & SecretarySep 06 '23Sale17.0611,000187,70444,066Sep 07 05:37 PM
Moxie DwightSVP, GC & SecretarySep 05 '23Sale17.8123,853424,92055,066Sep 07 05:37 PM
Foley Mark JCEOAug 03 '23Sale22.5726,279593,151840,375Aug 04 05:07 PM
Foley Mark JCEOJul 03 '23Sale24.9426,279655,333866,654Jul 05 09:11 PM
Schilke TobinCFOJul 03 '23Sale25.041,70142,59379,896Jul 05 09:11 PM
Kolaja Carey OConnorDirectorJun 15 '23Option Exercise18.122,50045,30019,061Jun 20 04:25 PM
Kolaja Carey OConnorDirectorJun 15 '23Sale28.242,50070,60016,561Jun 20 04:25 PM
Foley Mark JCEOJun 09 '23Sale30.7231,279960,928891,933Jun 13 08:09 PM
Sjuts Dustin SPresidentJun 09 '23Sale30.825,000154,096147,347Jun 13 08:09 PM
Schilke TobinCFOJun 02 '23Sale31.0050015,50080,828Jun 05 06:06 PM
Schilke TobinCFOJun 01 '23Sale30.572,70182,57081,328Jun 05 06:06 PM
Foley Mark JCEOMay 15 '23Sale34.5570,4472,433,725923,212May 16 08:29 PM
Schilke TobinCFOMay 15 '23Sale34.5521,401739,33884,029May 16 08:29 PM
Moxie DwightSVP, GC & SecretaryMay 15 '23Sale34.5521,401739,33869,165May 16 08:29 PM
Sjuts Dustin SPresidentMay 15 '23Sale34.5521,015726,003152,347May 16 08:29 PM
Schilke TobinCFOMay 01 '23Sale31.703,201101,47263,081May 02 04:01 PM